Circadian system - A novel diagnostic and therapeutic target in Parkinson's disease?

Movement Disorders

Volumn 31, Issue 3, 2016, Pages 260-269

  Videnovic, Aleksandar ^a   Willis, Gregory L ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Bronowski Institute of Behavioural Neuroscience   (Australia)

Author keywords

Chronobiology; Circadian; Clock genes; Parkinson's; Sleep

Indexed keywords

5 HYDROXYTRYPTOPHAN; ALPHA SYNUCLEIN; CORTICOTROPIN; DOPAMINE; HYDROCORTISONE; LEVODOPA; MELATONIN; N (2,4 DINITROPHENYL) 5 METHOXYTRYPTAMINE; OXIDOPAMINE; PER2 PROTEIN; SEROTONIN; TRANSCRIPTION FACTOR ARNTL; TRYPTOPHAN;

ACTIMETRY; BLOOD PRESSURE; BRADYKINESIA; BRAIN DEPTH STIMULATION; CARDIOVASCULAR FUNCTION; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM; CONTRAST SENSITIVITY; CORE TEMPERATURE; DAYTIME SOMNOLENCE; DEPRESSION; DYSKINESIA; HALLUCINATION; HEART RATE; HUMAN; HYPOKINESIA; LOCOMOTION; MEDLINE; MOTOR ACTIVITY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; PARASOMNIA; PARKINSON DISEASE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; REVIEW; SLEEP DISORDER; SLEEP WAKING CYCLE; SOMNOLENCE; SUBTHALAMIC NUCLEUS; SYSTEMATIC REVIEW; ANIMAL; BRAIN; DISEASE MODEL; PATHOPHYSIOLOGY; PHYSIOLOGY; SLEEP;

ANIMALS; BRAIN; CIRCADIAN RHYTHM; DISEASE MODELS, ANIMAL; HUMANS; PARKINSON DISEASE; SLEEP; SLEEP WAKE DISORDERS;

EID: 84958230948     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26509     Document Type: Review

References (83)

1. Dijk DJ, Lockley SW. Integration of human sleep-wake regulation and circadian rhythmicity. J Appl Physiol 2002;92:852-862.
2. Ralph MR, Foster RG, Davis FC, Menaker M. Transplanted suprachiasmatic nucleus determines circadian period. Science 1990;247:975-978.
3. Weaver DR. The suprachiasmatic nucleus: a 25-year retrospective. J Biol Rhythms 1998;13:100-112.
4. Hastings M, O'Neill JS, Maywood ES. Circadian clocks: regulators of endocrine and metabolic rhythms. J Endocrinol 2007;195:187-198.
5. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science 2003;302:255-259.
6. Wijnen H, Young MW. Interplay of circadian clocks and metabolic rhythms. Annu Rev Genet 2006;40:409-448.
7. Takahashi JS, Hong HK, Ko CH, McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet 2008;9:764-775.
8. Czeisler CA, Dumont M, Duffy JF, et al. Association of sleep-wake habits in older people with changes in output of circadian pacemaker. Lancet 1992;340:933-936.
9. Duffy JF, Zeitzer JM, Rimmer DW, Klerman EB, Dijk DJ, Czeisler CA. Peak of circadian melatonin rhythm occurs later within the sleep of older subjects. Am J Physiol Endocrinol Metab 2002;282:E297-303.
10. Hofman MA. The human circadian clock and aging. Chronobiol Int 2000;17:245-259.
11. Touitou Y, Haus E. Alterations with aging of the endocrine and neuroendocrine circadian system in humans. Chronobiol Int 2000;17:369-390.
12. Turek FW, Penev P, Zhang Y, van Reeth O, Zee P. Effects of age on the circadian system. Neurosci Biobehav Rev 1995;19:53-58.
13. van Coevorden A, Mockel J, Laurent E, et al. Neuroendocrine rhythms and sleep in aging men. Am J Physiol 1991;260:E651-661.
14. Drug therapy for Parkinson's disease. Med Lett Drugs Ther 1975;17:33-34.
15. Harper DG, Volicer L, Stopa EG, McKee AC, Nitta M, Satlin A. Disturbance of endogenous circadian rhythm in aging and Alzheimer disease. Am J Geriatr Psychiatry 2005;13:359-368.
16. Whitehead DL, Davies AD, Playfer JR, Turnbull CJ. Circadian rest-activity rhythm is altered in Parkinson's disease patients with hallucinations. Mov Disord 2008;23:1137-1145.
17. van Hilten JJ, Middelkoop HA, Kerkhof GA, Roos RA. A new approach in the assessment of motor activity in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:976-979.
18. van Hilten JJ, Kabel JF, Middelkoop HA, Kramer CG, Kerkhof GA, Roos RA. Assessment of response fluctuations in Parkinson's disease by ambulatory wrist activity monitoring. Acta Neurol Scand 1993;87:171-177.
19. van Hilten B, Hoff JI, Middelkoop HA, et al. Sleep disruption in Parkinson's disease. Assessment by continuous activity monitoring. Arch Neurol 1994;51:922-928.
20. van Hilten JJ, Hoogland G, van der Velde EA, Middelkoop HA, Kerkhof GA, Roos RA. Diurnal effects of motor activity and fatigue in Parkinson's disease. J Neurol Neurosurg Psychiatry 1993;56:874-877.
21. Bonuccelli U, Del Dotto P, Lucetti C, et al. Diurnal motor variations to repeated doses of levodopa in Parkinson's disease. Clin Neuropharmacol 2000;23:28-33.
22. Piccini P, Del Dotto P, Pardini C, D'Antonio P, Rossi G, Bonuccelli U. [Diurnal worsening in Parkinson patients treated with levodopa]. Riv Neurol 1991;61:219-224.
23. Nyholm D, Lennernas H, Johansson A, Estrada M, Aquilonius SM. Circadian rhythmicity in levodopa pharmacokinetics in patients with Parkinson disease. Clin Neuropharmacol 2010;33:181-185.
24. Struck LK, Rodnitzky RL, Dobson JK. Circadian fluctuations of contrast sensitivity in Parkinson's disease. Neurology 1990;40:467-470.
25. Wirz-Justice A, Da Prada M, Reme C. Circadian rhythm in rat retinal dopamine. Neurosci Lett 1984;45:21-25.
26. Dearry A, Burnside B. Dopaminergic regulation of cone retinomotor movement in isolated teleost retinas: I. Induction of cone contraction is mediated by D2 receptors. J Neurochem 1986;46:1006-1021.
27. Chen L, Yang G. Recent advances in circadian rhythms in cardiovascular system. Front Pharmacol 2015;6:71.
28. Oh YS, Kim JS, Park IS, et al. Association between nocturnal/supine hypertension and restless legs syndrome in patients with Parkinson's disease. J Neurol Sci 2014;344:186-189.
29. Ejaz AA, Sekhon IS, Munjal S. Characteristic findings on 24-h ambulatory blood pressure monitoring in a series of patients with Parkinson's disease. Eur J Intern Med 2006;17:417-420.
30. Devos D, Kroumova M, Bordet R, et al. Heart rate variability and Parkinson's disease severity. J Neural Transm 2003;110:997-1011.
31. Niwa F, Kuriyama N, Nakagawa M, Imanishi J. Circadian rhythm of rest activity and autonomic nervous system activity at different stages in Parkinson's disease. Auton Neurosci 2011;165:195-200.
32. Harada T, Ishizaki F, Nitta Y, et al. Circadian rhythm of cardiovascular autonomic nervous function in Parkinson's disease, early-onset Parkinsonism and multiple system atrophy. International Medical Journal 2006;13:131-133.
33. Harada T, Ishizaki F, Tachiki N, et al. Circadian rhythm of cradiovascular autonomic function in Parkinson's disease and multiple system atrophy. International Medican Journal 2005;12:37-39.
34. Mochizuki A, Komatsuzaki Y, Shoji S. Association of Lewy bodies and glial cytoplasmic inclusions in the brain of Parkinson's disease. Acta Neuropathol 2002;104:534-537.
35. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 1997;38(Suppl 2):2-7.
36. Langston J. The hypothalamus in Parkinson's disease. Ann Neurol 1978;3:129-133.
37. Suzuki K, Miyamoto T, Miyamoto M, Kaji Y, Takekawa H, Hirata K. Circadian variation of core body temperature in Parkinson disease patients with depression: a potential biological marker for depression in Parkinson disease. Neuropsychobiology 2007;56:172-179.
38. Seifried C, Boehncke S, Heinzmann J, et al. Diurnal variation of hypothalamic function and chronic subthalamic nucleus stimulation in Parkinson's disease. Neuroendocrinology 2013;97:283-290.
39. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson's disease. Mov Disord 1990;5:280-285.
40. Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson's disease. Clin Neuropharmacol 1988;11:512-519.
41. Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 1998;13:895-899.
42. Placidi F, Izzi F, Romigi A, et al. Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients. An ambulatory polysomnographic study. J Neurol 2008;255:1032-1037.
43. Abbott RD, Ross GW, White LR, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005;65:1442-1446.
44. Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Vanacore N, Meco G. Excessive daytime somnolence in Parkinson's disease. Follow-up after 1 year of treatment. Neurol Sci 2003;24:178-179.
45. Fabbrini G, Barbanti P, Aurilia C, Vanacore N, Pauletti C, Meco G. Excessive daytime sleepiness in de novo and treated Parkinson's disease. Mov Disord 2002;17:1026-1030.
46. Fronczek R, Overeem S, Lee SY, et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007;130:1577-1585.
47. Linazasoro G, Marti Masso JF, Suarez JA. Nocturnal akathisia in Parkinson's disease: treatment with clozapine. Mov Disord 1993;8:171-174.
48. Rye DB. Sleepiness and unintended sleep in Parkinson's disease. Curr Treat Options Neurol 2003;5:231-239.
49. Rye DB, Bliwise DL, Dihenia B, Gurecki P. FAST TRACK: daytime sleepiness in Parkinson's disease. J Sleep Res 2000;9:63-69.
50. Stack EL, Ashburn AM. Impaired bed mobility and disordered sleep in Parkinson's disease. Mov Disord 2006;21:1340-1342.
51. Videnovic A, Noble C, Reid KJ, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol 2014;71:463-469.
52. Bordet R, Devos D, Brique S, et al. Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin Neuropharmacol 2003;26:65-72.
53. Fertl E, Auff E, Doppelbauer A, Waldhauser F. Circadian secretion pattern of melatonin in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1991;3:41-47.
54. Fertl E, Auff E, Doppelbauer A, Waldhauser F. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa. J Neural Transm Park Dis Dement Sect 1993;5:227-234.
55. Bolitho SJ, Naismith SL, Rajaratnam SM, et al. Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. Sleep Med 2014;15:342-347.
56. Breen DP, Vuono R, Nawarathna U, et al. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol 2014;71:589-595.
57. Zhong G, Bolitho S, Grunstein R, Naismith SL, Lewis SJ. The relationship between thermoregulation and REM sleep behaviour disorder in Parkinson's disease. PLoS One 2013;8:e72661.
58. Aziz NA, Pijl H, Frolich M, Roelfsema F, Roos RA. Diurnal secretion profiles of growth hormone, thyrotrophin and prolactin in Parkinson's disease. J Neuroendocrinol 2011;23:519-524.
59. Aziz NA, Pijl H, Frolich M, Roelfsema F, Roos RA. Leptin, adiponectin, and resistin secretion and diurnal rhythmicity are unaltered in Parkinson's disease. Mov Disord 2011;26(4):760-761.
60. Czeisler CA, Allan JS, Strogatz SH, et al. Bright light resets the human circadian pacemaker independent of the timing of the sleep-wake cycle. Science 1986;233:667-671.
61. Klerman EB, Rimmer DW, Dijk DJ, Kronauer RE, Rizzo JF 3rd, Czeisler CA. Nonphotic entrainment of the human circadian pacemaker. Am J Physiol 1998;274:R991-996.
62. Harrell LE, Balagura S. The effects of dark and light on the functional recovery following lateral hypothalamic lesions. Life Sci 1974;15:2079-2087.
63. Willis GL, Turner EJ. Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study. Chronobiol Int 2007;24:521-537.
64. Paus S, Schmitz-Hubsch T, Wullner U, Vogel A, Klockgether T, Abele M. Bright light therapy in Parkinson's disease: a pilot study. Mov Disord 2007;22:1495-1498.
65. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. The retina in Parkinson's disease. Brain 2009;132:1128-1145.
66. Ben V, Bruguerolle B. Effects of bilateral striatal 6-OHDA lesions on circadian rhythms in the rat: a radiotelemetric study. Life Sci 2000;67:1549-1558.
67. Boulamery A, Simon N, Vidal J, Bruguerolle B. Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study. Chronobiol Int 2010;27:251-264.
68. Baier PC, Branisa P, Koch R, Schindehutte J, Paulus W, Trenkwalder C. Circadian distribution of motor-activity in unilaterally 6-hydroxy-dopamine lesioned rats. Exp Brain Res 2006;169:283-288.
69. Willis GL. Intraocular microinjections repair experimental Parkinson's disease. Brain Res 2008;1217:119-131.
70. Willis GL, Robertson AD. Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor. Pharmacol Biochem Behav 2004;79:413-429.
71. Willis GL, Kelly AM, Kennedy GA. Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model. Behav Brain Res 2008;193:37-47.
72. Hood S, Cassidy P, Cossette MP, et al. Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors. J Neurosci 2010;30:14046-14058.
73. Gravotta L, Gavrila AM, Hood S, Amir S. Global depletion of dopamine using intracerebroventricular 6-hydroxydopamine injection disrupts normal circadian wheel-running patterns and PERIOD2 expression in the rat forebrain. J Mol Neurosci 2011;45:162-171.
74. Hineno T, Mizobuchi M, Hiratani K, Inami Y, Kakimoto Y. Disappearance of circadian rhythms in Parkinson's disease model induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in dogs. Brain Res 1992;580:92-99.
75. Mizobuchi M, Hineno T, Kakimoto Y, Hiratani K. Increase of plasma adrenocorticotrophin and cortisol in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-treated dogs. Brain Res 1993;612:319-321.
76. Hayashi A, Matsunaga N, Okazaki H, et al. A disruption mechanism of the molecular clock in a MPTP mouse model of Parkinson's disease. Neuromolecular Med 2013;15:238-251.
77. Fifel K, Dkhissi-Benyahya O, Cooper HM. Lack of long-term changes in circadian, locomotor, and cognitive functions in acute and chronic MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) mouse models of Parkinson's disease. Chronobiol Int 2013;30:741-755.
78. Lax P, Esquiva G, Esteve-Rudd J, Otalora BB, Madrid JA, Cuenca N. Circadian dysfunction in a rotenone-induced parkinsonian rodent model. Chronobiol Int 2012;29:147-156.
79. Mattam U, Jagota A. Daily rhythms of serotonin metabolism and the expression of clock genes in suprachiasmatic nucleus of rotenone-induced Parkinson's disease male Wistar rat model and effect of melatonin administration. Biogerontology 2015;16:109-123.
80. Kudo T, Loh DH, Truong D, Wu Y, Colwell CS. Circadian dysfunction in a mouse model of Parkinson's disease. Exp Neurol 2011;232:66-75.
81. Willison LD, Kudo T, Loh DH, Kuljis D, Colwell CS. Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse model. Exp Neurol 2013;243:57-66.
82. Fifel K, Vezoli J, Dzahini K, et al. Alteration of daily and circadian rhythms following dopamine depletion in MPTP treated non-human primates. PLoS One 2014;9:e86240.
83. Fifel K, Cooper HM. Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson's disease. Neurobiol Dis 2014;71:359-369.